Back to Search
Start Over
Bioartificial Renal Epithelial Cell System (BRECS): A Compact, Cryopreservable Extracorporeal Renal Replacement Device.
- Source :
-
Cell medicine [Cell Med] 2012 Jan; Vol. 4 (1), pp. 33-43. - Publication Year :
- 2012
-
Abstract
- Renal cell therapy has shown clinical efficacy in the treatment of acute renal failure (ARF) and promise for treatment of end-stage renal disease (ESRD) by supplementing conventional small solute clearance (hemodialysis or hemofiltration) with endocrine and metabolic function provided by cells maintained in an extracorporeal circuit. A major obstacle in the widespread adoption of this therapeutic approach is the lack of a cryopreservable system to enable distribution, storage, and therapeutic use at point of care facilities. This report details the design, fabrication, and assessment of a Bioartificial Renal Epithelial Cell System (BRECS), the first all-in-one culture vessel, cryostorage device, and cell therapy delivery system. The BRECS was loaded with up to 20 cell-seeded porous disks, which were maintained by perfusion culture. Once cells reached over 5 × 10 <superscript>6</superscript> cells/disk for a total therapeutic dose of approximately 10 <superscript>8</superscript> cells, the BRECS was cryopreserved for storage at -80°C or -140°C. The BRECS was rapidly thawed, and perfusion culture was resumed. Near precryopreservation values of cell viability, metabolic activity, and differentiated phenotype of functional renal cells were confirmed post-reconstitution. This technology could be extended to administer other cell-based therapies where metabolic, regulatory, or secretion functions can be leveraged in an immunoisolated extracorporeal circuit.
Details
- Language :
- English
- ISSN :
- 2155-1790
- Volume :
- 4
- Issue :
- 1
- Database :
- MEDLINE
- Journal :
- Cell medicine
- Publication Type :
- Academic Journal
- Accession number :
- 24575327
- Full Text :
- https://doi.org/10.3727/215517912X653328